GENEVA — Global efforts to develop vaccines against a rare but dangerous form of Ebola are advancing after expert groups convened by the World Health Organization (WHO) recommended that two additional vaccine candidates be evaluated in an ongoing clinical trial in the Democratic Republic of the Congo (DRC).

The candidates are ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, and Moderna’s mRNA-1469. They have been recommended for further clinical evaluation against Bundibugyo virus, the virus responsible for the outbreak addressed by the trial.

WHO said this is the first time vaccines specifically designed to protect against Bundibugyo virus will be assessed during an outbreak of the disease. The candidates will enter the Tumaini trial only after the required national approvals. The recommendation is not a declaration that either vaccine has been proven effective or approved for general use.

How The Trial Is Designed

The Tumaini study is designed to evaluate multiple vaccine candidates within a single trial using a ring-vaccination approach. This strategy focuses on contacts of people with confirmed Bundibugyo virus disease, creating vaccination rings around identified cases to help assess whether the vaccines can prevent infection.

The DRC’s Institut National de Recherche Biomédicale is leading the study with international research partners and public-health organizations, including the University of Antwerp, WHO, Médecins Sans Frontières and Africa Centres for Disease Control and Prevention.

WHO reported that four vaccination rings were already in place when the announcement was made, with additional rings being prepared. The trial builds on the ring-vaccination approach used during the West Africa Ebola outbreak, when research in Guinea helped establish the effectiveness of the Ervebo vaccine against Zaire ebolavirus.

Research Also Examines Potential Treatments

Alongside vaccine research, the WHO-sponsored PARTNERS trial is evaluating potential treatments for patients with confirmed Bundibugyo virus disease. The study is assessing the monoclonal antibody MBP134, the antiviral remdesivir and a combination of the two. WHO said maftivimab is also expected to be added for evaluation, while a separate post-exposure prevention study involving obeldevisir is underway.

These studies are intended to generate evidence about possible tools for controlling the outbreak and improving patient outcomes. Their findings will need to be carefully assessed before conclusions can be drawn about safety, effectiveness and how the interventions should be used.

Why The Development Matters

Ebola disease can cause severe illness and death, and outbreaks place significant pressure on communities and health services. Vaccination, early identification of cases, infection prevention, contact tracing and supportive clinical care all remain important parts of outbreak response.

Bundibugyo virus is distinct from the Zaire ebolavirus targeted by the widely used Ervebo vaccine. This distinction matters because protection demonstrated against one Ebola virus species cannot automatically be assumed to apply to another.

WHO said initial findings from the treatment trials are expected in the coming months, while results from the vaccine trial are expected in early 2027. Until those data are available, the two new candidates should be regarded as experimental vaccines under evaluation.

Source: World Health Organization — Two New Candidate Vaccines To Join Ebola Trial.